Perspectives on brain-targeting drug delivery systems

Current Pharmaceutical Biotechnology

Volumn 13, Issue 12, 2012, Pages 2310-2318

  Guo, Liangran ^a,b   Ren, Jinfeng ^a   Jiang, Xinguo ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Adsorptive mediated transcytosis; Blood brain barrier; Brain targeting drug delivery systems; Chemical delivery systems; Nose to brain; Prodrugs; Receptor mediated transcytosis; Transporter mediated transcytosis

Indexed keywords

5,7 DICHLOROKYNURENIC ACID; ALLIUM CHINENSE EXTRACT; ANTHRACYCLINE; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN INHIBITOR; CEFALEXIN; CYCLOSPORIN; DIHYDROERGOTAMINE; DIPHTHERIA TOXOID CRM197; DIPYRIDAMOLE; DOPAMINE; ESTRADIOL; FLUOROURACIL; HORMONE ANTAGONIST; LOBRADIMIL; NC 1900; NIMODIPINE; PACLITAXEL; PEPTIDE; PLANT EXTRACT; PRODRUG; SMALL INTERFERING RNA; STEROID; SULFAFURAZOLE; SULFAMETHIZOLE; SULFASOMIDINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VINCA ALKALOID;

AMINO ACID TRANSPORT; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; COMA; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; NONHUMAN; TRANSCYTOSIS;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; MEMBRANE TRANSPORT PROTEINS; NASAL CAVITY;

EID: 84867739920     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112803341770     Document Type: Article

References (96)

1. Brasnjevic, I.; Steinbusch, H.W.M.; Schmitz, C.; Martinez-Martinez, P. Delivery of peptide and protein drugs over the bloodbrain barrier. Prog. Neurobiol., 2009, 87 (4), 212-251.
2. Nagane, M.; Pan, G.; Weddle, J.J.; Dixit, V.M.; Cavenee, W.K.; Huang, H.J. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res., 2000, 60(4), 847-853.
3. Palmer, A.M. Pharmacotherapy for Alzheimer's disease progress and prospects. TRENDS Pharmacol. Sci., 2002, 23(9), 426-433.
4. Thomas, B.; Beal, M.F. Parkinson's disease. Hum. Mol. Genet., 2007, 16(2), R183-R194.
5. Jones, A.R.;Shusta, E.V. blood-brain barrier transport of therapeutics via receptor-mediation. Pharmaceut. Res., 2007, 24(9), 1759-1771.
6. Pardridge, W.M. Drug targeting to brain. Pharmaceut Res., 2007, 24(9), 1733-1744.
7. Li, H.Y.; Qian, Z. M. Transferrin/Transferrin Receptor-Mediated Drug Delivery. Med Res Rev., 2002, 22(3), 225-250.
8. Soni, V.; Kohli, D.V.; Jain, S.K. Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil. J. Drug Target, 2005, 13(4), 245-250.
9. Huang, R.Q.; Qu, Y.H.; Ke, W.L.; Zhu, J.H.; Pei, Y.Y.; Jiang, C. Efficient gene delivery targeted to the brain using a transferrinconjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J., 2007, 21(4), 1117-1125.
10. Friden, P. M. Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier. J. Control Release, 1996, 46(1-2) 117-128.
11. Pang, Z.Q.; Lu, W.; Gao, H.L.; Hu, K.L.; Chen, J.; Zhang, C.L.; Gao, X.L.; Jiang, X.G.; Zhu, C.Q. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J. Control Release, 2008, 128(2), 120-127.
12. Lee, H. J.; Zhang, Y.; Zhu, C.; Duff, K.; Pardridge, W. M. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J. Cereb Blood Flow Metab., 2002, 22(2), 223-231.
13. Herz, J.; Bock, H.H. Lipoprotein receptors in the nervous system. Annu. Rev. Biochem., 2002, 71(1), 405-434.
14. Rip, J.; Boer, A.G. Differential receptor-mediated drug targeting to the diseased brain. Exp. Opin., 2009, 6(3), 227-237.
15. Fillebeen, C.; Descamps, L.; Dehouck, M.-P.; Fenart, L.; Benassa, M.; Spik, G.; Cecchelli, R.; Pierce, A. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J. Biol. Chem., 1999, 274(11), 7011-7017.
16. Huang, R.Q. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials, 2008, 29 (2), 238-246.
17. Spencer, B. J.; Verma, I. M. Targeted delivery of proteins across the blood-brain barrier. Proc. Natl. Acad. Sci. USA, 2007, 104(18), 7594-7599.
18. Sauer, I.; Dunay, I.R.; Weisgraber, K.; Bienert, M.; Dathe, M. An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells. Biochemistry, 2005, 44(6), 2021-2019.
19. Kreuter, J.; Alyautdin, R.N.; Kharkevich, D.A.; Ivanov, A.A. Passage of peptides through the blood-brainbarrier with colloidal polymer particles (nanoparticles). Brain Res., 1995, 674(1), 171-174.
20. Gulyaev, A.E.; Gelperina, S.E.; Skidan, I.N.; Antropov, A.S.; Kivman, G. Ya.; Kreuter, J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharmaceut. Res., 1999, 16(10), 1564-1569.
21. Kreuter, J. Nanoparticle systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47(1), 65-81.
22. Wilsona, B.; Samantaa, M.K.; Santhib, K.; Kumara, K.P.S.; Paramakrishnanc, N.; Suresha, B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res., 2008, 1200, 159-168.
23. Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.;Koch-Brandt, C.; Alyautdin, R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target, 2002, 10(4), 317-325.
24. Pardridge, W.M. shRNA and siRNA delivery to the brain. Adv. Drug Deliv. Rev., 2007, 59(2-3), 141-52.
25. Pardridge, W.M. Drug and gene targeting to the brain via bloodbrain barrier receptor-mediated transport systems. Int. Congr. Ser., 2005, 1277, 49-62.
26. Wu, D.F.; Yang, J.; Pardridge, W.M. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest., 1997, 100(7), 1804-1812
27. Beduneau, A.; Saulnier, P.; Benoit, J.P. Active targeting of brain tumors using nanocarriers. Biomaterials., 2007, 28 (33), 4947-4967.
28. Gaillard, P.J.; Visser, C.C.; Boer, A.G. Diphtheria toxin receptor-targeted brain drug delivery, Int. Congr. Ser., 2005, 1277, 185-198.
29. Gaillard, P.J.; de Boer, A.G. A novel opportunity for targeted drug delivery to the brain. J. control release, 2006, 116, e60-62.
30. Gaillard, P.J.; Brink, A.; de Boer, A.G. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions. World Patent 2,004,069,870, October, 2, 2004.
31. Gaillard, P.J.; de Boer, A.G. 2B-Trans technology: targeted drug delivery across the blood-brain barrier. Methods Mol. Biol., 2008, 437, 161-75.
32. Gaillard, P.J., Visser, C.C.; Boer, de A.G. Targeted delivery across the blood-brain barrier, Exp. Opin. Drug Deliv., 2005, 2(2), 299-309.
33. Lentz, T.L.; Smith, A.L.;Crick, J.; Tignor, G.H. Is the acetylcholine receptor a rabies virus receptor. Science, 1982, 215(4529), 182-184.
34. Kumar, P.; Wu, H.Q.; McBride, J.L.;Jung, K.E.; Kim, M.H.; Davidson, B.L.; Lee, S.K.; Shankar, P.; Manjunath, N. Transvascular delivery of small interfering RNA to the central nervous system. Nature, 2007, 448(7149), 39-43.
35. Krieger M. Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu. Rev. Biochem., 1999, 68, 523-558.
36. Husemann, J.; Samuel, C. Silverstein expression of scavenger receptor class b, type i, by astrocytes and vascular smooth muscle cells in normal adult mouse and human brain and in alzheimer's disease brain. Am. J. Patholo., 2001, 158(3), 825-832.
37. Nakagawa-Toyama, Y.; Hirano, K.; Okamoto, Y.; Nishida, M. Expression of high-density lipoprotein receptors, scavenger receptor class B type I in human central nervous system, Xllth International Symposium on Atherosclerosis, Stockholm, Sweden, June 25-29, 2000.
38. Kratzer, I.; Wernig, K.; Panzenboeck, U.; Bernhart, E.; Reicher, H.; Wronski, R.; Windisch, M.; Hammer, A.; Malle, E.; Zimmer, A.; Sattler, W. Apolipoprotein A-I coating of protamineoligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J. Control Release, 2007, 117(3), 301-311.
39. Kreuter, J.; Hekmatara, T.; Dreis, S.; Vogel, T.; Gelperina, S. Langer, K. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 toalbumin nanoparticles enables drug transport into the brain. J. Control Release., 2007, 118 (1), 54-58.
40. Abulrob, A.; Sprong, H.; Van Bergen en Henegouwen, P.; Stanimirovic, D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem., 2005, 95(4), 1201-1214.
41. Abulrob, A.; Zhang, J.; Tanha, J.; MacKenzie, R.; Stanimirovic, D. Single domain antibodies as blood-brain barrier delivery vectors. Int. Congr. Ser., 2005, 1277, 212-223.
42. Kang, Y.S.; Pardridge, W.M. Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin. Pharm. Res., 1994, 11(9), 1257-1264.
43. Xie, Y.L.; Lu, W.; Jiang, X.G. Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. Behav. Brain Res., 2006, 173(1), 76-84.
44. Pardridge, W.M.; Triguero, D.; Buciak, J. L. Endorphin chimeric peptides: Transport through the blood-brain barrier in vivo and cleavage of bisulfide linkage by brain. Endocrinology, 1990, 126(2), 977-984.
45. Lu, W.; Sun, Q.; Wan, J.; She, Z.; Jiang, X.G. Cationic albuminconjugated pegylated nanoparticles allow gene delivery into brain tumors via i.v. administration. Cancer Res., 2006, 66(24), 1187-1188.
46. Lu, W.; Zhang, Y.; Tan, Y-Z.; Hu, K.-L.; Jiang, X.-G.; Fu, S.-K. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J. Controlled Release., 2005, 107(3), 428-448.
47. Gynther, M.; Ropponen, J.; Laine, K.; Leppänen, J.; Haapakoski, P.; Peura, L.; Järvinen, T.; Rautio, J. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats. J. Med. Chem., 2009, 52(10), 3348-3353.
48. Enerson, B.E.; Drewes, L.R. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J. Pharm. Sci., 2003, 92(8), 1531-1544.
49. Smith, Q.R. Carrier-mediated transport to enhance drug delivery to brain. Int. Congr. Ser., 2005, 1277, 63-74.
50. Pardridge, W.M. Blood-brain barrier carrier-mediated transport and brainmetabolism of amino acids. Neurochem. Res., 1998, 23(5), 635-644.
51. Tamai, I.; Tsuji, A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci., 2000, 89(11), 1371-1388.
52. Graff, C.L.; Pollack, G.M. Drug transport at the blood-brain barrier and the choroid plexus. Curr. Drug Metab., 2004, 5(1), 95-108.
53. Tsuji, A.; Tamai, I. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev., 1999, 36(2-3), 277-290.
54. Tsuji, A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. Neurotherapeutics, 2005, 2(1), 54-62.
55. Nutt, J.G.; Woodward, W.R.; Hammerstad, J.P.; Carter, J.H.; Anderson, J.L. The "ON-OFF" phenomenon in Parkinson's disease. relation tolevodopa absorption and transport. N. Engl. J. Med., 1984, 310(8), 483-488.
56. Nawashiro, H.; Otani, N.; Uozumi, Y.; Ooigawa, H.; Toyooka, T.; Suzuki, T.; Katoh, H.; Tsuzuki, N.; Ohnuki, A.; Shima K.; Shinomiya, N.; Matsuo, H.; Kanaiet, Y. High expression of L-type amino acid transporter 1 in infiltrating glioma cells. Brain Tumor Pathol., 2005, 22(2), 89-91.
57. Battaglia, G.; La Russa, M.; Bruno, V.; Arenare, L.; Ippolito, R.; Copani, A.; Bonina, F.; Nicoletti, F. Systemically administered Dglucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain. Res., 2000, 860(1-2), 149-156.
58. Fernandez, C.; Nieto, O.; Fontenla, J. A.; Rivas, E.; de Ceballos, M. L.; Fernandez-Mayoralas, A. Synthesis of glycosyl derivatives as dopamine rodrugs: interaction with glucose carrier GLUT-1. Org. Biomol. Chem., 2003, 1(5), 767-771.
59. Tamai, I.; Tsuji, A. Drug delivery through the blood-brain barrier. Adv. Drug Deliv. Rev., 1996, 19 (3), 401-424.
60. Sakane, T.; Akizuki, M.; Yamashita, S.; Nadai, T.; Hashida, M.; Sezaki, H. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem. Pharm. Bull., 1991, 39(9), 2456-2458.
61. Sakane, T.; Akizuki, M.; Yoshida, M.; Yamashita, S.; Nadai, T.; Hashida, M.; Sezaki, H. Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J. Pharm. Pharmacol., 1991, 43(6), 449-451.
62. Sakane, T.; Yamashita, S.; Yata, N.; Sezaki, H. Transnasal delivery of 5-fluorouracil to the brain in the rat, J. Drug Targeting, 1999, 7 (3), 233-240.
63. Wang, Y.; Aun, R.; Tse, F.L.S. Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm. Drug Dispos., 1998, 19, 571-575.
64. Wang, X.M.; He, H.B.; Wei, L.; Tang, X. Evaluation of braintargeting for the nasal delivery of estradiol by the microdialysis method. Int. J. Pharm., 2006, 317 (1), 40-46.
65. Dahlin, M.; Jansson, B.; Björk, E. Levels of dopamine in blood and brain following nasal administration to rats. Eur. J. Pharm. Sci., 2001, 14 (1), 75-80.
66. Wang, Feng.; Jiang X.G.; Lu, W. Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int. J. Pharm., 2003, 263(1-2), 1-7.
67. Zhang, Q. Z.; Jiang, X.G.; Jiang, W.M.; Lu, W.; Su, L.N.; Shi, Z.Q. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int. J. Pharm., 2004, 275(1-2), 85-96.
68. Zhao, H.M.; Liu X.F.; Mao. X.W.; Chen, C.F. Intranasal delivery of nerve growth factor to protect the central nervous system against acute cerebral infarction. Chin Med. Sci. J. 2004, 19(4), 257-261.
69. Stewart, W.B. Labelling of olfactory bulb glomeruli following horseradish peroxidase lavage of the nasal cavity. Brain Res., 1985, 347(1), 200-203.
70. Broadwell R.D.; Balin B.J. Endocytic and exocytic pathways of the neuronal secretory process and trans-synaptic transfer of wheat germ agglutinin-horseradish peroxidase in vivo. J. Comp. Neurol., 1985, 242(4), 632-650.
71. Draghia, R.; Caillaud, C.; Manicom, R.; Pavirani, A.; Kahn, A.; Poenaru, L. Gene delivery into the central nervous system by nasal instillation in rats. Gene Ther., 1995, 2(6), 418-423.
72. Gao, X, L.; Wu, B.X.; Zhang, Q.Z.; Chen, J.; Zhu, J.H.; Zhang, W.W.; Rong, Z.X.; Chen, H.Z.; Jiang, X.G. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J. Control Release., 2007, 121(3), 156-167.
73. Wu, H.; Hu, K.; Jiang, X. From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin. Drug Deliv., 2008, 5(10), 1159-1168.
74. Frey, W, H.; Liu, J.; Chen, X.; Thorne, R.G.; Fawcett, J.R. Delivery of 125I-NGF to the Brain via the Olfactory Route. Drug Deliv., 1997, 4(2), 87-92.
75. Bodor, N.; Buchwald, P. Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease. Drug Discov. Today, 2002, 7(14), 776-774.
76. Bodor, N.; Buchwald, P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev., 1999, 36(2-3), 229-254.
77. Shanmuganathan, K.; Koudriakova, T.; Nampalli, S.; Du, J. F.; Gallo, J. M.; Schinazi, R.F.; Chu, C. K. Enhanced brain delivery of anti2HIV nucleoside 2-F-ara-ddI by xanthine oxidase mediated biotransformation. J. Med. Chem., 1994, 37 (6), 821-827.
78. Yoshikawa, T.; Sakaeda, T.; Sugawara, T.; Hirano, K.; Stella, V. J. A novel chemical delivery system for brain targeting. Adv. Drug Deliv. Rev., 1999, 36(2-3), 255-275.
79. Prokai-Tatrai, K.; Kim, H.-S.; ProkaiL. The utility of oligopeptidase in brain-targeting delivery of an enkephalin analogue by prodrug design. Open Med. Chem J., 2008, 2, 97-100.
80. Rautio, J.; Laine, K.; Gynther, M.; Savolainen, J. Prodrug approaches for CNS delivery. AAPS J., 2008, 10(1), 92-102.
81. Oldendorf, W. H.; Hyman, S.; Braun, L.; Oldendorf, S. Z. Bloodbrain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science, 1972, 178(64), 984-986.
82. Greig, N. H.; Genka, S. E.; Daly, M.; Sweeney, D. J.; Rapoport, S. I. Physicochemical and pharmacokinetic parameters ofseven lipophilic chlorambucil esters designed for brain penetration. Cancer Chemother. Pharmacol., 1990, 25(5), 311-319.
83. Genka, S.; Deutsch, J.; Shetty, U. H.; Stahle, P. L.; John, V.; Lieberburg, I. M.; Ali-Osmant, F.; Rapoport, S. I.; Greig, N. H. Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil. Clin. Exp. Metastasis., 1993, 11(2),131-140.
84. Anderson, B. D. Prodrugs for improved CNS delivery. Adv. Drug Deliv. Rev., 1996, 19(2), 171-202.
85. Temsamani, J.; Scherrmann, J.-M.; Rees, A. R.; Kaczorek, M. Brain drug delivery technologies: novel approaches for transporting therapeutics. PSTT., 2000, 3(5), 155-162.
86. Bellavance, M.-A.; Blanchette, M.; Fortin, D. Recent advances in blood-brain barrier disruption as a cns delivery strategy. AAPS. J., 2008, 10(1), 166-177.
87. Bartus, R. T.; Elliott, P. J.; Hayward, N. J.; Dean, R. L.; Mcewen, E.; Fisher, S. K. Bradykinin permeation of the BBB: Evidence for a sensitive auto-regulated, receptor-mediated system. Immunopharmacology, 1996, 33(1-3), 270-278.
88. Elliott, P. J.; Hayward, N. J.; Dean, R. L.; Bartus, R. T. Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, RMP-7. Immunopharmacology, 1996, 33(1-3), 205-208.
89. Bartus, R. T.; Elliott, P. J.; Dean, R. L.; Hayward, N. J.; Nagle, T. L.; Huff, M. R.; Nodgrass, P. A. S.; Blunt, D. G. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol., 1996, 142(1), 14-28.
90. Vykhodtseva, N.; Mc Dannold, N.; Hynynen, K. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics, 2008, 48 (4), 279-296.
91. Demeulea, M.; Réginaa, A.; Jodoina, J.; Laplantea, A.; Claude, D.; Bertheletb, F.; Moghrabic, A.; Beliveaua, R.Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the bloodbrain barrier. Vascular Pharmacol., 2002, 38 (6), 339-348.
92. Miller, D. S.; Bauer, B.; Hartz, A. M. S. Modulation of Pglycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol. Rev., 2008, 60(2), 196-209.
93. Ford, J.M.; Hait, W.N. Pharmacologic circumvention of multidrug resistance. Cytotechnology., 1993, 12(1-3), 171-212.
94. Béduneau, A.; Hindré, F.; Clavreul, A. Brain targeting using novel lipid nanovectors. J. Control Release., 2008, 126 (1), 44-49.
95. Shi, N.; Pardridge, W. M. Noninvasive gene targeting to the brain. Proc. Natl. Acad. Sci. USA., 2000, 97(13), 7567-7572.
96. Zhang, Y.; Zhang, Y.-F.; Bryant, J.; Charles, A.; Boado, R. J.; Pardridge, W. M. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res., 2004, 10, 3667-3677.